×
About 629,344 results
Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839299
JAMA Inohara T, Xian Y et. al.

Jan 26th, 2018 - Although non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used to prevent thromboembolic disease, there are limited data on NOAC-related intracerebral hemorrhage (ICH). To assess the association between preceding oral anticoagulant use (warfarin, NOACs, and no oral anticoagulants [OACs]) and in-hospital mortality among patients with ICH. Retrospective cohort study of 141 31...

Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney...
https://doi.org/10.1053/j.gastro.2017.05.046
Gastroenterology Klatte DCF, Gasparini A et. al.

Jun 6th, 2017 - Proton pump inhibitors (PPI) have been associated with acute kidney injury and recent studies suggest that they may be associated with the risk of chronic kidney disease (CKD). We performed a retrospective analysis using the Stockholm creatinine measurements database, which contains information on diagnoses, dispensation claims, and laboratory test results for all citizens in the Stockholm regi...

Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism
https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2754091
JAMA Internal Medicine; Rob F. Walker, et al

Nov 30th, 2019 - Testosterone therapy is increasingly prescribed in patients without a diagnosis of hypogonadism. This therapy may be associated with increased risk of venous thromboembolism (VTE) through several mechanisms, including elevated hematocrit levels, which increase blood viscosity.

Fasting Triglycerides & Glucose Index: A Useful Screening Test for Assessing Insulin Resistance in Patients Diagnosed with Rheumatoid Arthritis & Systemic Lupus Erythematosus
https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-019-0495-x
Diabetology & Metabolic Syndrome; Contreras-Haro B, et al

Nov 26th, 2019 - Insulin resistance (IR) is frequently observed in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). In clinical practice, IR assessment is limited to a low proportion of patients due to cost and equipment and technical expertise requirements. The surrogate index of triglycerides and glucose (TyG index) has been validated in non-rheumatic populations, showing adequat...

Cannabidiol as a potential treatment for psychosis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843725/
Therapeutic Advances in Psychopharmacology; Davies C, et al

Nov 7th, 2019 - Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treatment of psychotic disorders and they remain the mainstay of our treatment arsenal for psychosis. However, traditional antipsychotics are associated wi...

Scientists design device for oral delivery of injections
https://www.nih.gov/news-events/nih-research-matters/scientists-design-device-oral-delivery-injections

Oct 28th, 2019 - Biologic drugs are complex medications produced from living organisms or their parts. They include vaccines and drugs to treat conditions like rheumatoid arthritis, psoriasis, and cancer. Some biologic drugs, like insulin, can only be delivered by injection. If taken by mouth, stomach acid would destroy the drug before it could take effect.

FDA approves Fiasp® for use in insulin infusion pumps for adults with type 1 or type 2 diabetes
https://www.novonordisk-us.com/media/news-releases.html?122974

Oct 21st, 2019 - Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has expanded the label for Fiasp® (insulin aspart injection) 100 u/mL to include use in insulin infusion pumps for the improvement of glycemic control in adults with type 1 or type 2 diabetes.1 Fiasp®, a rapid-acting insulin, was approved by the FDA in 2017 for use by intravenous infusion under supervision by a health...

Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease - AMBER
https://www.acc.org/latest-in-cardiology/clinical-trials/2019/10/08/14/26/amber

Oct 7th, 2019 - The AMBER trial showed that the potassium binder patiromer was effective at allowing more patients to remain on spironolactone.

Optimizing Postprandial Glucose Management in Adults With Insulin-Requiring Diabetes: Report and Recommendations
https://academic.oup.com/jes/article/3/10/1942/5581189
Journal of the Endocrine Society;

Oct 6th, 2019 - Faster-acting insulins, new noninsulin drug classes, more flexible insulin-delivery systems, and improved continuous glucose monitoring devices offer unprecedented opportunities to improve postprandial glucose (PPG) management and overall care for adults with insulin-treated diabetes. These developments led the Endocrine Society to convene a working panel of diabetes experts in December 2018 to...

Anticoagulation: Updated Guidelines for Outpatient Management
https://www.aafp.org/afp/2019/1001/p426.html
American Family Physician;

Sep 30th, 2019 - Anticoagulation therapy is recommended for preventing, treating, and reducing the recurrence of venous thromboembolism, and preventing stroke in persons with atrial fibrillation. Direct oral anticoagulants are first-line agents for eligible patients for treating venous thromboembolism and preventing stroke in those with nonvalvular atrial fibrillation. Vitamin K antagonists are recommended for ...

Protecting Patients from Elder Abuse Scams
https://www.aafp.org/afp/2019/1001/p438.html
American Family Physician;

Sep 30th, 2019 - Living on my own continues to be very important to me, even though I'm getting older and am sometimes forgetful. I manage pretty well with the help of my son, who visits me weekly, and my family doctor, who I see monthly for my hypertension, stomach reflux problems, prediabetes, and high cholesterol. I try to manage my forgetfulness with the help of a pill box so that I remember to take my medi...

Screening and Management of the Hyperandrogenic Adolescent
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Screening-and-Management-of-the-Hyperandrogenic-Adolescent

Sep 23rd, 2019 - Although androgen excess can manifest in many ways, the most common and recognizable symptoms are hirsutism and acne. Reports of hirsutism and acne should be taken seriously because of their possible association with medical disorders, their substantial effect on self-esteem and quality of life, and the potential for psychosocial morbidity. In patients with symptoms of androgen excess, the diff...

FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes
https://www.novonordisk-us.com/media/news-releases.html?122973

Sep 19th, 2019 - Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus® (semaglutide) tablets 7 mg or 14 mg for adults with type 2 diabetes that along with diet and exercise may improve blood sugar (glucose).1 Rybelsus® is the first and only glucagon-like peptide-1 (GLP-1) analog in a pill and a new option for adults with type 2 diabetes who are not achieving their ...

Psoriatic Arthritis - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK547710/

Sep 19th, 2019 - Psoriatic arthritis (PsA) is chronic inflammatory arthritis associated with psoriasis (PsO) and found in about 20 to 30% of such patients.[1] It shares many clinical features with other spondyloarthropathies and also rheumatoid arthritis (RA). It is usually seronegative, but a small percentage of patients may be positive for rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodi...

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
https://www.nejm.org/doi/full/10.1056/NEJMoa1911303
The New England Journal of Medicine; McMurray, J. et. al.

Sep 18th, 2019 - BACKGROUND In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 ...

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30311-0/fulltext
The Lancet Diabetes & Endocrinology; Lingvay, I. et. al.

Sep 16th, 2019 - Existing guidelines for management of type 2 diabetes recommend a patient-centred approach to guide the choice of pharmacological agents. Although glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter-2 (SGLT2) inhibitors are increasingly used as second-line agents, direct comparisons between these treatments are insufficient. In the SUSTAIN 8 trial, we compared the...

Urinary Incontinence in Women: Evaluation and Management
https://www.aafp.org/afp/2019/0915/p339.html
American Family Physician;

Sep 14th, 2019 - Urinary incontinence is a common problem among women worldwide, resulting in a substantial economic burden and decreased quality of life. The Women's Preventive Services Initiative is the only major organization that recommends annual screening for urinary incontinence in all women despite low to insufficient evidence regarding effectiveness and accuracy of methods. No other major organization ...

Xeris Pharmaceuticals Receives U.S. Fda Approval For Gvoke™ (Glucagon), The First Ready-to-use Stable Liquid Glucagon For Severe Hypoglycemia
https://xerispharma.gcs-web.com/news-releases/news-release-details/xeris-pharmaceuticals-receives-us-fda-approval-gvoketm-glucagon

Sep 9th, 2019 - Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that it has received regulatory approval from the U.S. Food and Drug Administration (FDA) for GVOKE™ (glucagon) injection, its ready-to-use, room-temperature stable liquid gl...

Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION, Number 785
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Screening-and-Management-of-Bleeding-Disorders-in-Adolescents-With-Heavy-Menstrual-Bleeding

Aug 21st, 2019 - Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life. If obstetrician–gynecologists suspect that a patient has a bleeding disorder, they should work in coordination with a hematologist for laboratory evaluation and medical management. Evaluation of adolescent girls who present with heavy men...

Diabetes Technology: Review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes
https://annals.org/aim/fullarticle/2748278/diabetes-technology-review-2019-american-diabetes-association-standards-medical-care
Annals of Internal Medicine;

Aug 12th, 2019 - Description: The American Diabetes Association (ADA) annually updates its Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes. Methods: The ADA Professional Practice Committee comprises physicians, adult and pediatric endocrinol...

Should Adults With Prediabetes Be Prescribed Metformin To Prevent Diabetes Mellitus? No: Evidence Does Not Show Improvements in Patient-Oriented Outcomes
https://www.aafp.org/afp/2019/0801/p136.html
American Family Physician; Brown, S.

Aug 1st, 2019 - Prediabetes is not a disease. It is a risk factor for a disease (diabetes mellitus). Most people with so-called prediabetes will not develop diabetes within five years.1 The American Diabetes Association (ADA) definition of prediabetes now includes a threshold value in fasting glucose (100 to 125 mg per dL [5.5 to 6.9 mmol per L]), two-hour glucose tolerance test (140 to 199 mg per dL [7.8 to 1...

Should Adults With Prediabetes Be Prescribed Metformin To Prevent Diabetes Mellitus? Yes: High-Quality Evidence Supports Metformin Use in Persons at High Risk
https://www.aafp.org/afp/2019/0801/p134.html
American Family Physician; Moin, T.

Aug 1st, 2019 - A surge in the prevalence of prediabetes1 highlights the importance of improving prediabetes awareness and engaging in strategies to lower the risk of type 2 diabetes mellitus. Based on evidence from randomized controlled trials and observational studies, U.S. and international guidelines advocate for the use of medications in addition to intensive lifestyle interventions to prevent diabetes.2,...

ACG Clinical Guideline: Hereditary Hemochromatosis
https://journals.lww.com/ajg/Fulltext/2019/08000/ACG_Clinical_Guideline__Hereditary_Hemochromatosis.11.aspx
Kowdley, K. et. al.

Aug 1st, 2019 - Hereditary hemochromatosis (HH) is one of the most common genetic disorders among persons of northern European descent. There have been recent advances in the diagnosis, management, and treatment of HH. The availability of molecular diagnostic testing for HH has made possible confirmation of the diagnosis for most patients. Several genotype-phenotype correlation studies have clarified the diffe...

Updates to the 2019 Standards of Medical Care in Diabetes Issued Today by the American Diabetes Association
http://www.diabetes.org/newsroom/press-releases/2019/updates-standards-medical-care.html

Jul 30th, 2019 - The American Diabetes Association® (ADA) issued important updates to the 2019 Standards of Medical Care in Diabetes (Standards of Care) today, in annotations as the Living Standards of Care, with the changes focusing on new metrics for continuous glucose monitoring (CGM) utilization and new medication options and recommendations for youth and adults with type 2 diabetes. The updates were inform...

Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study
https://annals.org/aim/article-abstract/2739786/sodium-glucose-cotransporter-2-inhibitors-risk-severe-urinary-tract-infections
Annals of Internal Medicine;

Jul 29th, 2019 - Background: Prior studies evaluating risk for severe urinary tract infections (UTIs) with sodium–glucose cotransporter-2 (SGLT-2) inhibitors have reported conflicting findings. Objective: To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those initiating use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like...

FDA approves Feraccru® with a broad label of treating iron deficiency in adults
https://www.shieldtherapeutics.com/wp-content/uploads/2019/07/STX-Feraccru-FDA-approval-26.07.19.pdf

Jul 25th, 2019 - Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency, announces that the U.S. Food and Drug Administration (FDA) has approved its lead product Feraccru® / Accrufer® for the treatment of iron deficiency in adults. With this broad label approval Accrufer® (as the product will be marketed in the USA) has taken a big step towar...

New Approaches Improve Diagnosis, Prediction of Type 2 Diabetes
https://www.patientcareonline.com/t2-diabetes/new-approaches-improve-diagnosis-prediction-type-2-diabetes

Jul 25th, 2019 - The accuracy of diagnosing and predicting type 2 diabetes mellitus (T2DM) and prediabetes could be improved by applying multiple or alternative measures, according to studies presented at the American Diabetes Association (ADA) Scientific Sessions meeting in San Francisco, CA, in June. Joon Ha, PhD, Laboratory of Biological Modeling, National Institute of Diabetes and Digestive and Kidney Disea...

AHA's "Life's Simple 7" Reduces Heart Failure Risk
https://www.patientcareonline.com/cardiovascular-disease/ahas-lifes-simple-7-reduces-heart-failure-risk

Jul 24th, 2019 - The incidence of congestive heart failure (HF) was reduced by 47% in a group of individuals adhering to a combination of healthy lifestyle practices; among individuals who adhered to an “ideal” combination of those practices, HF was reduced by 55%. In a recent study that analyzed the impact of the American Heart Association’s (AHA) Life’s Simple 7 (LS7) healthy behaviors on HF risk reduction, t...

BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
https://investor.lilly.com/news-releases/news-release-details/baqsimitm-glucagon-nasal-powder-3-mg-first-and-only-nasally

Jul 23rd, 2019 - The U.S. Food and Drug Administration (FDA) has approved BAQSIMI™ (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia in people with diabetes ages four years and above, Eli Lilly and Company (NYSE: LLY) announced today. BAQSIMI is the first and only nasally administered glucagon, and it was designed with severe hypoglycemia rescue in mind. It is compact, portable and ready to ...

Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke
https://jamanetwork.com/journals/jama/article-abstract/2738553
JAMA

Jul 22nd, 2019 - Question Does intensive glucose control improve functional outcome in patients with hyperglycemic acute ischemic stroke? Findings This randomized clinical trial included 1151 adults who received either intensive treatment of hyperglycemia (target blood glucose concentration of 80-130 mg/dL) or standard treatment of hyperglycemia (target glucose concentration of 80-179 mg/dL). The proportio...

Effects of Nutritional Supplements and Dietary Interventions on Cardiovascular Outcomes: An Umbrella Review and Evidence Map
https://annals.org/aim/article-abstract/2737825/effects-nutritional-supplements-dietary-interventions-cardiovascular-outcomes-umbrella-review-evidence
Annals of Internal Medicine; Khan, S. et. al.

Jul 8th, 2019 - Background: The role of nutritional supplements and dietary interventions in preventing mortality and cardiovascular disease (CVD) outcomes is unclear. Purpose: To examine evidence about the effects of nutritional supplements and dietary interventions on mortality and cardiovascular outcomes in adults. Data Sources: PubMed, CINAHL, and the Cochrane Library from inception until March 20...

Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study
https://www.bmj.com/content/366/bmj.l4414
BMJ Sabia, S. et. al.

Jun 11th, 2019 - Objectives To examine the association between the Life Simple 7 cardiovascular health score at age 50 and incidence of dementia. Design Prospective cohort study. Setting Civil service departments in London (Whitehall II study; study inception 1985-88). Participants 7899 participants with data on the cardiovascular health score at age 50. Exposures The cardiovascular health score inc...

Vitamin D Supplementation and Prevention of Type 2 Diabetes
https://www.nejm.org/doi/10.1056/NEJMoa1900906
New England Journal of Medicine; Pittas. A., et al

Jun 6th, 2019 - Observational studies support an association between a low blood 25-hydroxyvitamin D level and the risk of type 2 diabetes. However, whether vitamin D supplementation lowers the risk of diabetes is unknown. METHODS We randomly assigned adults who met at least two of three glycemic criteria for prediabetes (fasting plasma glucose level, 100 to 125 mg per deciliter; plasma glucose level 2 hou...

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
http://care.diabetesjournals.org/content/42/6/1147
Diabetes Care; Danne, T. et. al.

May 31st, 2019 - Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent studies, particularly in individuals with type 1 diabetes, have demonstrated increases in the absolut...

Metformin | PubChem
https://pubchem.ncbi.nlm.nih.gov/compound/metformin

May 10th, 2019 - A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification.

Pediatric Systemic Lupus Erythematosus Workup
https://emedicine.medscape.com/article/1008066-workup

Apr 26th, 2019 - The initial laboratory evaluation should include a complete blood count (CBC) with platelets and reticulocyte count; a complete chemistry panel to evaluate electrolytes, liver, and kidney function; urine analysis; and a measure of acute phase reactants (eg, erythrocyte sedimentation rate [ESR] or C-reactive protein [CRP]).

Reprogramming Cells to Make Insulin
https://academic.oup.com/jes/article/3/6/1214/5476582
Journal of Endocrine Society;

Apr 23rd, 2019 - Type 1 diabetes is a disease characterized by the destruction of insulin-secreting β-cells in the pancreas. Individuals are treated for this disease with lifelong insulin replacement. However, one attractive treatment possibility is to reprogram an individual’s endogenous cells to acquire the ability to secrete insulin, essentially replacing destroyed β-cells. Herein, we review the literature o...

A Meta-Analysis of 46 Studies Identified by the FDA Demonstrates that Soy Protein Decreases Circulating LDL and Total Cholesterol Concentrations in Adults
https://academic.oup.com/jn/article-abstract/149/6/968/5475972?redirectedFrom=fulltext
The Journal of Nutrition; Mejia, S. et. al.

Apr 21st, 2019 - Certain plant foods (nuts and soy protein) and food components (viscous fibers and plant sterols) have been permitted by the FDA to carry a heart health claim based on their cholesterol-lowering ability. The FDA is currently considering revoking the heart health claim for soy protein due to a perceived lack of consistent LDL cholesterol reduction in randomized controlled trials.

Lupus Erythematosus - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK535405/

Apr 19th, 2019 - The acute form of systemic lupus erythematosus (SLE) differs from the chronic form. It disseminates differently, and it is highly fatal. Kaposi was the first in recognizing SLE in 1872, and then Pernet described it in 1908. Before that time SLE was considered to be a non-fatal disfiguring skin disease. It is now to be considered a chronic inflammatory disease characterized by a course of altern...

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
https://www.nejm.org/doi/full/10.1056/NEJMoa1811744?query=recirc_curatedRelated_article

Apr 13th, 2019 - Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.

Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials
https://onlinelibrary.wiley.com/doi/10.1111/dom.13743
Diabetes, Obesity and Metabolism;

Apr 9th, 2019 - Diabetic kidney disease (DKD) still remains a progressive condition that is associated with higher risk of end‐stage kidney disease and significant cardiovascular morbidity and mortality. Twelve cardiovascular outcome trials in type 2 diabetes (T2D) have been published to date. Most trials with dipeptidyl‐peptidase inhibitors (SAVOR‐TIMI 53 with saxagliptin, EXAMINE with alogliptin, TECOS with ...

Association Among Dietary Supplement Use, Nutrient Intake, and Mortality Among U.S. Adults
https://annals.org/aim/article-abstract/2730525/association-among-dietary-supplement-use-nutrient-intake-mortality-among-u
Chen, F. et. al.

Apr 8th, 2019 - Background: The health benefits and risks of dietary supplement use are controversial. Objective: To evaluate the association among dietary supplement use, levels of nutrient intake from foods and supplements, and mortality among U.S. adults. Design: Prospective cohort study. Setting: NHANES (National Health and Nutrition Examination Survey) data from 1999 to 2010, linked to Nation...

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
https://jnccn.org/view/journals/jnccn/17/4/article-p302.xml
Benson, A. et. al.

Mar 31st, 2019 - Incidence and mortality rates for cancer overall are declining, but both incidence and mortality rates for hepatocellular carcinoma (HCC) are increasing.1,2 Risk factors for development of HCC include infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV), and cirrhosis of the liver (eg, alcohol cirrhosis).3 Metabolic disorders (ie, obesity, diabetes, impaired glucose metabolism,...

Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism
https://www.nejm.org/doi/full/10.1056/NEJMoa1813865
The New England Journal of Medicine; van der Pol, L. et. al.

Mar 20th, 2019 - Pulmonary embolism is one of the leading causes of maternal death in the Western world. Because of the low specificity and sensitivity of the d-dimer test, all pregnant women with suspected pulmonary embolism undergo computed tomographic (CT) pulmonary angiography or ventilation–perfusion scanning, both of which involve radiation exposure to the mother and fetus. Whether a pregnancy-adapted alg...

Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi™ (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-us-fda-approval-sunositm

Mar 19th, 2019 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Sunosi™ (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). Once-daily Sunosi is approved with doses of 75 mg and 150 mg for patients with narcolepsy and doses of 37.5 mg, 75 mg, and 1...

FDA Grants Genentech’s Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
https://www.marketwatch.com/press-release/fda-grants-genentechs-tecentriq-in-combination-with-abraxane-accelerated-approval-for-people-with-pd-l1-positive-metastatic-triple-negative-breast-cancer-2019-03-08

Mar 7th, 2019 - Genentech, a member of the Roche Group (six:RO)(six:ROG)(otcqx:RHHBY), today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq [®] (atezolizumab) plus chemotherapy (Abraxane [®] [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adults with unresectable locally advanced or metasta...

Reduction Of Type 1 And Type 2 Myocardial Infarctions In Patients Treated With Alirocumab: Insights From The Odyssey Trial
http://www.onlinejacc.org/content/73/9_Supplement_1/4
White, H. et. al.

Feb 28th, 2019 - LDL cholesterol (LDL-C) reduction with statins and PCSK9 inhibitors reduces risk of myocardial infarction (MI), but effects on specific types of MI are unknown. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab (ALI) with placebo (PBO) in 18924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C despite intensive statin therapy. ALI reduced the primary composite endpoin...

Hypoglycemia - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK534841/
Mathew, P. et. al.

Feb 28th, 2019 - Hypoglycemia is often defined by a plasma glucose concentration below 70 mg/dL; however, signs and symptoms may not occur until plasma glucose concentrations drop below 55 mg/dL. The symptoms of Whipple's triad have been used to describe hypoglycemia since 1938. For Whipple's triad, the practitioner must first recognize symptoms of hypoglycemia, then obtain low blood glucose, and finally, demo...